Stay updated on Neoadjuvant Anti-PD1 in Head & Neck Melanoma Clinical Trial

Sign up to get notified when there's something new on the Neoadjuvant Anti-PD1 in Head & Neck Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Neoadjuvant Anti-PD1 in Head & Neck Melanoma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    6 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the Phase IIa/IIb clinical trial of NC-6004 in combination with pembrolizumab for subjects with recurrent or metastatic squamous cell carcinoma of the head and neck who have failed platinum or a platinum-containing regimen.
    Difference
    0.1%
    Check dated 2024-06-06T14:18:45.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to provide a detailed explanation of eligibility criteria, including examples such as a person's general health condition or prior treatments. Additionally, it now includes a link for general information about clinical research.
    Difference
    20%
    Check dated 2024-05-22T20:54:29.000Z thumbnail image
  8. Check
    43 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T21:59:00.000Z thumbnail image

Stay in the know with updates to Neoadjuvant Anti-PD1 in Head & Neck Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Neoadjuvant Anti-PD1 in Head & Neck Melanoma Clinical Trial page.